Clinical Trials Logo

Filter by:
NCT ID: NCT03504982 Not yet recruiting - Clinical trials for Coronary Artery Disease

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Start date: May 30, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the effect of multiple doses of vericiguat on the QTc interval in patients with stable CAD (coronary artery disease).

NCT ID: NCT03447756 Recruiting - Clinical trials for Diabetic Peripheral Neuropathy

Titration Study of ABX-1431

Start date: October 2, 2017
Phase: Phase 1
Study type: Interventional

This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.

NCT ID: NCT03442725 Recruiting - Renal Impairment Clinical Trials

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

Start date: February 9, 2018
Phase: Phase 1
Study type: Interventional

Renal excretion is a minor elimination route of telotristat etiprate. So this trial is intended to assess the drug behaviour in subjects with decreased renal function. This is a staged study with Part B contingent upon the results of Part A. Part A will enrol a total of 16 subjects, eight with severely impaired renal function and eight healthy subjects. Part B with enrol a total of 16 subjects, eight subjects in each additional renal function group, i.e. mildly impaired renal function group and moderately impaired group.

NCT ID: NCT03383211 Recruiting - HIV Infections Clinical Trials

Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers

IMMUNEO
Start date: June 16, 2017
Phase: N/A
Study type: Observational

Maternal infections affect the basal immune status of neonates. One of the possible mechanism is the fetomaternal microchimerism, in which some cells and active substances are exchanged bi-directionally between maternal and fetal circulation through placenta. Even in the absence of a direct (vertical) transmission of pathogens to fetuses, certain infections make the neonates more prone to allergies and some adverse events of early vaccinations. We postulate that the basal immune status of neonates born to HIV and LTBI infected mothers is primed by gestational exposure to immunological active molecules, which could results in an altered response to early BCG vaccination. Transcripts expression identified by RNA sequencing are compared between sets of mother-child and their respective umbilical cord blood, and between groups of infected and non-infected pairs.

NCT ID: NCT03303313 Recruiting - Clinical trials for Atypical Hemolytic Uremic Syndrome

A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Start date: September 19, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.

NCT ID: NCT03241108 Recruiting - Clinical trials for Rheumatoid Arthritis

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Start date: May 10, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis

NCT ID: NCT03230786 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type 2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of metformin. The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and United Kingdom

NCT ID: NCT03230292 Active, not recruiting - Clinical trials for Chronic Plaque Psoriasis

This is a Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis.

Start date: July 3, 2017
Phase: Phase 2
Study type: Interventional

This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.

NCT ID: NCT03219957 Recruiting - Hepatitis C Clinical Trials

Study of AT-527 in Healthy and HCV-Infected Subjects

Start date: July 6, 2017
Phase: Phase 1
Study type: Interventional

This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.

NCT ID: NCT03215277 Recruiting - Clinical trials for Ankylosing Spondylitis

Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis.

Start date: October 4, 2017
Phase: Phase 2
Study type: Interventional

Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS)